Biotech Superstar Dies

Alejandro Zaffaroni, who launched companies that developed birth control pills, microarrays, and transdermal drug patches, has died at age 91.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ZAFFARONI FOUNDATIONA successful biotech entrepreneur whose companies pioneered the technology behind transdermal patches, DNA chips, and the birth control pill, died at his home in California at the age of 91. Alejandro Zaffaroni was the man behind Alza, Affymetrix, Affymax, and many other successful firms. “He always started with a big idea behind his companies and then adapted on the ground to the reality of what could be achieved,” Isaac Stein, a business partner of Zaffaroni, told The New York Times.

According to the Times, Zaffaroni was born in Uruguay and became an orphan at age 18. He came to the U.S. for his graduate work in biochemistry on corticosteroids. During the 1950s and '60s he became an accomplished scientist at Syntex Pharmaceuticals. Writing for The Scientist in 1988, David Moreau, the first managing director of Syntex in the U.K., described how Zaffaroni’s advances in paper chromatography of steroids contributed to the development of “fluocinolone acetonide (known worldwide as Synalar), the oral progestins that made the birth-control pill possible, non-virilizing androgens such as oxymetholone (still used for the treatment of aplastic anemia), paramethasone and many others.”

Zaffaroni’s business acumen and congenial nature helped him to lure successful academics to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies